INDIANAPOLIS--(BUSINESS WIRE)--OBS Medical announced today that the Food and Drug Administration has granted 510(k) clearance for the company to market its next generation patient deterioration early warning system (VisensiaTM) in the United States.
INDIANAPOLIS--(BUSINESS WIRE)--OBS Medical announced today that the Food and Drug Administration has granted 510(k) clearance for the company to market its next generation patient deterioration early warning system (VisensiaTM) in the United States.
